238 results on '"Rafei, Hind"'
Search Results
2. Umbilical Cord Blood Transplantation
3. List of Contributors
4. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
5. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles
6. Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
7. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
8. Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march
9. Contributors
10. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.
11. Landscape of Immunotherapy in Genitourinary Malignancies
12. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles
13. Current Landscape of Immunotherapy in Genitourinary Malignancies
14. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
15. Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies.
16. Hereditary myeloid malignancies
17. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial.
18. 1289 Immune hallmarks construction via non-negative matrix factorization with data-driven functional validations and translational implications
19. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen
20. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
21. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
22. 8 - Umbilical Cord Blood Transplantation
23. Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
24. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+B cell tumors: a phase 1/2 trial
25. Targeting advanced urothelial carcinoma-developing strategies
26. Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer.
27. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
28. Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia
29. Disseminated intravascular coagulation-like reaction following rituximab infusion
30. DA‐EPOCH‐R for post‐transplant lymphoproliferative disorders
31. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
32. DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells
33. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies
34. Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies
35. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results
36. Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells
37. Chimeric Antigen Receptor-Engineered NK Cells Overcome CD226 Downregulation As an Immune Escape Mechanism in Acute Myeloid Leukemia
38. CD70 CAR NK Cells in the Treatment of Multiple Myeloma
39. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis
40. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
41. Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study
42. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse
43. A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab
44. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial
45. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
46. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation
47. The Future of Cellular Therapy
48. Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
49. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis
50. AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.